A study published Sept. 23 in Cancers found that IV vitamin C and mistletoe therapy were each associated with a lower adjusted hazard of death among women receiving integrative palliative care for breast cancer. That association does not establish that either treatment prolonged patients’ lives.
Donghun Lee and colleagues analyzed 748 women treated at Yeom Chang Hwan Hospital in Seoul between April 2011 and May 2024. During a median follow-up of 10 months, 109 patients died; the mean follow-up was 20.2 months. The therapies were administered alongside conventional cancer treatment, not in place of it.
After adjusting for age, metastasis, triple-negative status, chemotherapy, surgery, radiotherapy and other palliative treatments, the researchers found that IV vitamin C was associated with a 43.9% lower mortality hazard and mistletoe with a 53.7% lower hazard. Those figures describe adjusted associations in this cohort, not a demonstrated reduction in deaths caused by either therapy. The analysis classified patients as unexposed to a treatment until they first received it.
Nicolas Hulscher described the findings in an Oct. 26 X post as “DRAMATICALLY IMPROVED SURVIVAL.” His Focal Points article also notes that the observational study cannot establish causality and calls for randomized trials. The study authors describe the findings as grounds for further investigation of the therapies as potential additions to standard care.
Comments